AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16881990 — intervention group
Group type: EXPERIMENTAL
Intervention: Water aerobics
Number of subjects: 390
Study 16881990 — intervention group
Group type: COMPARATOR
Intervention: Land-based physical exercise program
Number of subjects: 390
Study 15956927 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (Ado) infusion over 10 min at systemic pressure during IAC bypass surgery
Number of subjects: 34
Study 15956927 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion over 10 min at systemic pressure during IAC bypass surgery
Number of subjects: 34
Study 11172846 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg esterified estrogen
Number of subjects: 53
Study 11172846 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen
Number of subjects: 53
Study 11172846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 9644978 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4-8 mg (mean 5.7 mg)
Number of subjects: 78
Study 9644978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 7880945 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 0
Study 7880945 — intervention group
Group type: COMPARATOR
Intervention: Seasonal variation
Number of subjects: 0
Study 3264528 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ketorolac
Number of subjects: 32
Study 3264528 — intervention group
Group type: COMPARATOR
Intervention: 50 mg pethidine
Number of subjects: 32
Study 3264528 — intervention group
Group type: COMPARATOR
Intervention: 100 mg pethidine
Number of subjects: 32
Study 29316888 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training (SMT)
Number of subjects: 236
Study 29316888 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV)
Number of subjects: 236
Study 29316888 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 236
Study 27856335 — intervention group
Group type: EXPERIMENTAL
Intervention: Active grape formulation
Number of subjects: 10
Study 27856335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (formulation free of polyphenols)
Number of subjects: 10
Study 26032843 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued pharmacist intervention for another 24 months
Number of subjects: 54
Study 26032843 — intervention group
Group type: COMPARATOR
Intervention: One-time educational materials (control group)
Number of subjects: 54
Study 23496848 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to consume low‐mercury/high‐DHA fish (n=18)
Number of subjects: 61
Study 23496848 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice + grocery store gift cards (GC) to purchase fish (n=17)
Number of subjects: 61
Study 23496848 — intervention group
Group type: COMPARATOR
Intervention: Control messages (n=20)
Number of subjects: 61
Study 21594208 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing followed by local application of 10% doxycycline hyclate (SRP-D)
Number of subjects: 45
Study 21594208 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 45
Study 19012973 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory processing problem checklist (parental report)
Number of subjects: 104
Study 19012973 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory processing problems
Number of subjects: 104
Study 17122241 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection technique (Group S) with 25 mL of mepivacaine 1%
Number of subjects: 60
Study 17122241 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-injection technique (Group D) with 12.5 mL of mepivacaine 1% injected twice
Number of subjects: 60
Study 17122241 — intervention group
Group type: COMPARATOR
Intervention: Superficial peroneal nerve block (Group S)
Number of subjects: 60
Study 17122241 — intervention group
Group type: COMPARATOR
Intervention: Superficial peroneal nerve block (Group D)
Number of subjects: 60
Study 17122241 — intervention group
Group type: COMPARATOR
Intervention: Tibial nerve block (Group D)
Number of subjects: 60
Study 17122241 — intervention group
Group type: COMPARATOR
Intervention: Paresthesias during block procedure
Number of subjects: 60
Study 15685822 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin/cyclophosphamide followed by paclitaxel alone or combined with gemcitabine for four cycles each
Number of subjects: 3000
Study 15685822 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel alone or combined with gemcitabine
Number of subjects: 3000
Study 15685822 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin/cyclophosphamide
Number of subjects: 3000
Study 11182006 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin and Ethambutol (RE)
Number of subjects: 223
Study 11182006 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin, Ethambutol, and Isoniazid (REH)
Number of subjects: 223
Study 9692413 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release low dose aspirin (75 mg)
Number of subjects: 36
Study 9692413 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional formulation aspirin (75 mg)
Number of subjects: 36
Study 9692413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7837399 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose epidural fentanyl (HEF)
Number of subjects: 25
Study 7837399 — intervention group
Group type: COMPARATOR
Intervention: Epidural mepivacaine (M)
Number of subjects: 25
Study 2898502 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antiseptic care
Number of subjects: 0
Study 2898502 — intervention group
Group type: COMPARATOR
Intervention: 24 h cephalosporin prophylaxis
Number of subjects: 0
Study 30912721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative MRI
Number of subjects: 200000
Study 30912721 — intervention group
Group type: COMPARATOR
Intervention: Control (without intraoperative MRI)
Number of subjects: 200000
Study 28923623 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 40
Study 28923623 — intervention group
Group type: COMPARATOR
Intervention: MMF (50% reduction)
Number of subjects: 40
Study 28923623 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (conversion from MMF)
Number of subjects: 40
Study 25973704 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-speaking patients
Number of subjects: 1177
Study 23799913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine-ER 20% responders
Number of subjects: 0
Study 23799913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine-ER 20% nonresponders
Number of subjects: 0
Study 23799913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21745116 — intervention group
Group type: EXPERIMENTAL
Intervention: MPCNL irrigation and clearance system
Number of subjects: 60
Study 21745116 — intervention group
Group type: COMPARATOR
Intervention: EMS ultrasound/ballistic trajectory lithotripsy and clearance system
Number of subjects: 60
Study 19901118 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg
Number of subjects: 435
Study 19901118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study 16309749 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy with myringotomy and ventilation tube insertion (study group)
Number of subjects: 45
Study 16309749 — intervention group
Group type: COMPARATOR
Intervention: Adenoidectomy with myringotomy (control group)
Number of subjects: 45
Study 15270993 — intervention group
Group type: EXPERIMENTAL
Intervention: Racial and opinion minority members in small-group discussions
Number of subjects: 357
Study 15270993 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups with racial- and opinion-minority members
Number of subjects: 357
Study 15270993 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with racially diverse friends and classmates
Number of subjects: 357
Study 10912607 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective dorsal rhizotomy
Number of subjects: 0
Study 10912607 — intervention group
Group type: COMPARATOR
Intervention: Intensive physical therapy
Number of subjects: 0
Study 9084455 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/m2 dose of pegylated-liposomal doxorubicin for the first cycle, followed by 20 mg/m2 every 3 weeks
Number of subjects: 43
Study 9084455 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/m2 dose of pegylated-liposomal doxorubicin every 3 weeks
Number of subjects: 43
Study 1532127 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly concentrated ethyl esters of n-3 fatty acids (85% eicosapentaenoic acid and docosahexaenoic acid)
Number of subjects: 23
Study 1532127 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (56% linoleic and 26% oleic acid)
Number of subjects: 23
Study 4096777 — intervention group
Group type: EXPERIMENTAL
Intervention: Derotation brace
Number of subjects: 42
Study 4096777 — intervention group
Group type: COMPARATOR
Intervention: No brace (control condition)
Number of subjects: 42
Study 31543516 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 0
Study 31543516 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake with Ca:Mg ratio between 1.7 and 2.5
Number of subjects: 0
Study 30541254 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril arginine
Number of subjects: 40
Study 30541254 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 40
Study 30541254 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 40
Study 26355169 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium‐incorporated implants (Xpeed)
Number of subjects: 60
Study 26355169 — intervention group
Group type: COMPARATOR
Intervention: Control resorbable blasted media (RBM) implants
Number of subjects: 60
Study 23342969 — intervention group
Group type: EXPERIMENTAL
Intervention: Brassica rapa ethanol extract (BREE) 2 g/day
Number of subjects: 58
Study 23342969 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch, 2 g/day)
Number of subjects: 58
Study 22555246 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic web-based weight-loss program
Number of subjects: 309
Study 22555246 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced web-based weight-loss program
Number of subjects: 309
Study 22555246 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 309
Study 18977811 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin (BoNT)
Number of subjects: 60
Study 18977811 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tizanidine (TZD)
Number of subjects: 60
Study 18977811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17478080 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 17
Study 17478080 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 17
Study 14969403 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 1593
Study 14969403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1593
Study 12370455 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 76
Study 12370455 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic Antidepressants (TCA)
Number of subjects: 76
Study 12370455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 9650873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic toothbrush (group B)
Number of subjects: 62
Study 9650873 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (group A)
Number of subjects: 62
Study 10187881 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose potassium insulin (GKI) infusion at 100 mL/h consisting of 16 U human soluble insulin and 20 mmol potassium chloride in 500 mL 10% glucose
Number of subjects: 53
Study 10187881 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 53
Study 1854670 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of D3-alpha-tocopheryl acetate for 14 consecutive days (n = 6)
Number of subjects: 24
Study 1854670 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of D3-alpha-tocopheryl acetate for 14 consecutive days (n = 8)
Number of subjects: 24
Study 1854670 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of D3-alpha-tocopheryl acetate for 14 consecutive days (n = 6)
Number of subjects: 24
Study 1854670 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 6)
Number of subjects: 24
Study 6843194 — intervention group
Group type: EXPERIMENTAL
Intervention: MIM system
Number of subjects: 519
Study 6843194 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 519
Study 30855640 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone treatment
Number of subjects: 2821
Study 30855640 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2821
Study 29390054 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly irinotecan hydrochloride and docetaxel
Number of subjects: 0
Study 27349715 — intervention group
Group type: EXPERIMENTAL
Intervention: Local liposomal bupivacaine (LB) - 20 mL of bupivacaine/10 mL of saline solution
Number of subjects: 82
Study 27349715 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 82
Study 27349715 — intervention group
Group type: COMPARATOR
Intervention: Control group (FNB)
Number of subjects: 82
Study 27349715 — intervention group
Group type: EXPERIMENTAL
Intervention: Local liposomal bupivacaine (LB)
Number of subjects: 82
Study 24929613 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy hip extension strength training (HET)
Number of subjects: 27
Study 24929613 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy hip flexion strength training (HFT)
Number of subjects: 27
Study 24929613 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 27
Study 22190678 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 16
Study 22190678 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 16
Study 22190678 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 16
Study 20459820 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-monthly monitoring
Number of subjects: 0
Study 20459820 — intervention group
Group type: COMPARATOR
Intervention: Three-monthly monitoring (Control)
Number of subjects: 0
Study 18250253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (1-minute bolus of 0.26 mg/kg, followed by a maintenance infusion of 0.25 mg/kg/h)
Number of subjects: 33
Study 18250253 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment with lamotrigine (300 mg)
Number of subjects: 33
Study 18250253 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 33
Study 18250253 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lamotrigine)
Number of subjects: 33
Study 15914532 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 pmol/kg.min ghrelin
Number of subjects: 7
Study 15914532 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 pmol/kg.min ghrelin
Number of subjects: 7
Study 15914532 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study 12022597 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic GBP
Number of subjects: 48
Study 12022597 — intervention group
Group type: COMPARATOR
Intervention: Open GBP
Number of subjects: 48
Study 9875583 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (H) 6 months, twice a week
Number of subjects: 1053
Study 9875583 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (R) plus Pyrazinamide (Z) 3 months, twice a week
Number of subjects: 1053
Study 9875583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1053
Study 8275793 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure ventilation (NPV) applied by an airtight jacket (pneumosuit), 5 hours a day, 5 consecutive days a week for 4 weeks
Number of subjects: 13
Study 8275793 — intervention group
Group type: COMPARATOR
Intervention: Control group (in-hospital pulmonary rehabilitation program for 4 weeks)
Number of subjects: 13
Study 2743201 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine hydrocarbonate
Number of subjects: 100
Study 2743201 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine hydrochloride plus 0.5% bupivacaine hydrochloride
Number of subjects: 100
Study 1095306 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg diftalone daily for 2 weeks
Number of subjects: 70
Study 1095306 — intervention group
Group type: COMPARATOR
Intervention: 100 mg indomethacin daily for 2 weeks
Number of subjects: 70
Study 31888740 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA‐enriched medium/long‐chain triglyceride (MCT/LCT) ILE (Lipidem/Lipoplus® 200 mg/ml, B. Braun Melsungen AG)
Number of subjects: 160
Study 31888740 — intervention group
Group type: COMPARATOR
Intervention: MCT/LCT ILE (Lipofundin® MCT/LCT/Medialipide® 20%, B. Braun Melsungen AG)
Number of subjects: 160
Study 29100193 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin plus gemcitabine (EG)
Number of subjects: 118
Study 29100193 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine (PG)
Number of subjects: 118
Study 25608246 — intervention group
Group type: EXPERIMENTAL
Intervention: X-Stop
Number of subjects: 96
Study 25608246 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive decompression
Number of subjects: 96
Study 23568228 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-CBT counseling with mDOT for 24 weeks
Number of subjects: 204
Study 23568228 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-CBT counseling alone
Number of subjects: 204
Study 23568228 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 204
Study 20497239 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 25 mg/day p.o. for 6 months
Number of subjects: 27
Study 20497239 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormone replacement)
Number of subjects: 27
Study 18257399 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy and radiation therapy
Number of subjects: 70
Study 18257399 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy and surgery
Number of subjects: 70
Study 17233363 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine
Number of subjects: 80
Study 17233363 — intervention group
Group type: COMPARATOR
Intervention: 0.5% hyperbaric tetracaine
Number of subjects: 80
Study 17233363 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study 12502993 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraPrep
Number of subjects: 60
Study 12502993 — intervention group
Group type: COMPARATOR
Intervention: povidone iodine (PI)
Number of subjects: 60
Study 10714612 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac‐Na effervescent (fast-release NSAID)
Number of subjects: 20
Study 10714612 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac‐Na effervescent (fast-release NSAID)
Number of subjects: 20
Study 10714612 — intervention group
Group type: COMPARATOR
Intervention: 50 mg diclofenac tablets (control)
Number of subjects: 20
Study 10714612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8854192 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 5: biphasic injection of 100 mL of iohexol 300 (g/100 mL) at a flow rate of 1.5 mL/second followed by 25 mL at 2 mL/second; total iodine load = 37.5 g, with a scan delay of 70 seconds
Number of subjects: 121
Study 8854192 — intervention group
Group type: COMPARATOR
Intervention: Protocol 1-4 (not specified in detail)
Number of subjects: 121
Study 1339054 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 24
Study 4003916 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 ppm ozone exposure
Number of subjects: 13
Study 4003916 — intervention group
Group type: COMPARATOR
Intervention: Air exposure (control)
Number of subjects: 13
Study 30577864 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G‐CSF) treatment (5 μg/kg/day for 5 days followed by every 3 days) in patients with partial response (PR) to corticosteroids.
Number of subjects: 268
Study 30577864 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G‐CSF) treatment in patients with null response (NR) to corticosteroids.
Number of subjects: 268
Study 30577864 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (40 mg/day for 1 week) followed by 28 days of treatment and tapering for an additional 2 weeks in patients with partial response (PR).
Number of subjects: 268
Study 30577864 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with partial response (PR) to corticosteroids.
Number of subjects: 268
Study 30577864 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with null response (NR) to corticosteroids.
Number of subjects: 268
Study 26676273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pink-veneered zirconia abutments (CR-P, SR-P)
Number of subjects: 44
Study 26676273 — intervention group
Group type: COMPARATOR
Intervention: Nonveneered zirconia abutments (CR-W, SR-W)
Number of subjects: 44
Study 25294223 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Lactobacillus brevis KB290 (about 6 billion colony-forming units)
Number of subjects: 1089
Study 25294223 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group A)
Number of subjects: 1089
Study 23237122 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat Pap smear after a normal Pap smear
Number of subjects: 0
Study 23237122 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat Pap smear after an inadequate smear result
Number of subjects: 0
Study 23237122 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade squamous intra-epithelial lesions (HSILs)
Number of subjects: 0
Study 23237122 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with abnormal cytology
Number of subjects: 0
Study 20307378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex
Number of subjects: 337